The content on this site is intended for healthcare professionals only
Prof Peeters talks to ecancertv at ASCO 2014 about the results of the results from a large federally funded phase III study demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cancer and no KRAS mutations.
Read the article, watch the press conference or see the expert to expert interview for more.
ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
OncoAlert Round Up for August 25th - 31st, 2023
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
The current status of multiple myeloma diagnosis and treatment
